Milestone Shares Close at $0.52 After Analysts Cut Price Targets
Key Facts
Milestone Pharmaceuticals shares closed at $0.52 on Nov. 13, 2026, according to EL7 data, in a session that followed the company’s announcement of third-quarter results. On Nov. 16, TD Cowen cut its price target to $5 from $8 but maintained its Buy rating, according to Investing.com, citing Reuters. Piper Sandler also cut its target to $3 from $7, while maintaining its Overweight rating. Piper Sandler linked its cut to lower CARDAMYST sales. The revisions put the performance of the emerging commercial product at the center of analysts’ assessment of the stock.
The company posted net CARDAMYST revenue of $1.0 million in the third quarter of 2026, up 73% from the second quarter ended June 30, 2026, according to the company’s statement. In its quarterly filing with the U.S. Securities and Exchange Commission, Milestone said product revenue was $1.0 million for the three months ended Sept. 30 and $1.8 million for the nine months ended on the same date. The company recorded no product revenue in the corresponding periods of 2025. The comparison shows that the product began generating revenue in 2026, with third-quarter revenue higher than the previous quarter. But sales growth did not prevent the quarterly loss from widening.
Milestone’s net loss in the third quarter was $25.8 million, or $0.18 per share, compared with a loss of $11.9 million, or $0.12 per share, in the third quarter of 2025, according to the company’s statement. Selling, general and administrative expenses rose to $24.2 million from $7.9 million in the corresponding period. The company attributed the increase mainly to additional employee and professional-services costs and other operating expenses related to the CARDAMYST launch. This puts the cost of the launch alongside revenue growth in assessing the quarter’s results. It also explains the higher spending behind the larger loss compared with a year earlier, without establishing that the loss exceeded analysts’ expectations.
As launch indicators, the company said about 3,400 CARDAMYST prescriptions had been written since its launch, by about 1,600 prescribers, as of Nov. 13, 2026. It added that payer coverage had reached about two-thirds of commercially insured people. Prescription and prescriber counts offer indicators of the product’s market reach, while payer coverage reflects the scope of people covered commercially. These figures show an expanding base of use and coverage alongside the product’s revenue generation in 2026. At the same time, the quarterly results show that the company continues to bear expenses related to its launch.
Milestone announced measures to cut operating expenses by about 30%, saying their completion is expected by the first quarter of 2027. The target follows a rise in third-quarter selling, general and administrative expenses to $24.2 million, compared with $7.9 million a year earlier, an increase the company said was related mainly to the CARDAMYST launch. The company has thus identified cost cuts as its next operational step amid product sales growth and increased spending associated with the launch. The statement did not specify the dollar amount of the savings in the information provided. The company’s target for completing the measures is the first quarter of 2027.
On clinical development, the company said its pivotal Phase 3 ReVeRA-301 trial is on schedule. The trial is evaluating etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular response. Milestone expects to announce topline data in the second half of 2028. That timeline follows the expected completion of operating expense reduction measures in the first quarter of 2027. The company’s announced milestones therefore include near-term cost reductions, followed by an initial readout from the Phase 3 trial in the second half of 2028.